🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)

RecruitingNAAges 19 Years - anyAllSeoul National University Hospital
NCT05577845 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Safety \& Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * mid and low rectal cancer (AV\<15cm) * stage II, III, preop long-course CCRT, then ileostomy repair * about 1\~12 months after operation (no stomy) * about 1\~6 months after ileostomy repair * major LARS Exclusion Criteria: * recurred rectal cancer * stage IV * IBD * uncontrolled preoperative fecal incontinence or constipation
💊

What it tests

  • Ramosetron
📍

Where

1 site
Seoul National University Hospital
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy